Abstract
Introduction
Digoxin is commonly used for rate control in atrial fibrillation (AF). Despite a relative paucity of data from large randomized controlled trials, several guidelines have recommended its use. The 2014 American Heart Association/American College of Cardiology guidelines suggest the use of digoxin alone in sedentary patients (class I, level of evidence: C) or in combination with either a beta-blocker or non-dihydropyridine calcium channel blocker for non-sedentary individuals and individuals with heart failure (HF) (class IIA, level of evidence: B) [1] . The European Society of Cardiology also recommends its long-term use in both sedentary and active AF patients (class IIA, level of evidence: C) [2] . However, there is growing controversy regarding the association between digoxin and mortality. Earlier investigations of digoxin in HF patients did not demonstrate an increased risk of mortality with digoxin use [3] . However, recent studies suggested an increased risk of mortality with digoxin among AF patients [4, 5] . It will be difficult to design a randomized controlled trial that would evaluate these findings and thus a meta-analysis may provide useful insight and information regarding digoxin use in AF patients. To evaluate the association of digoxin with mortality in AF, we conducted a systematic review and meta-analysis to assess whether digoxin use in AF patients is independently associated with an increased risk of mortality.
Methods

Study design
Protocol. We undertook a systematic review and meta-analysis of randomized controlled trials and observational studies assessing digoxin use in AF patients and its association with mortality.
Data collection. Two reviewers performed an electronic search of MEDLINE, EMBASE, GoogleScholar, Web of Science for published manuscripts until December 15, 2014. We reviewed abstracts from major cardiology meetings held between 2001 and 2014. No limits were used for the search. We also searched the references of the related articles, as well as links to related articles to gather additional articles. We also performed an extensive search of the narrative reviews of the relevant topics. The search terms included variants of "atrial fibrillation", "atrial flutter", "atrial arrhythmia", "supraventricular tachycardia", "digoxin", "digitalis", "cardiac glycoside", "digitoxin", "foxglove", "mortality", "death", "outcomes", "risk factor", "clinical trials", and "prognosis" using text words and Medical Subject Headings (MeSH) terms. We also reviewed editorials and letters related to the topic to identify published and unpublished data. There were no restrictions applied to language, publication date, or publication status. The search was performed without any language restrictions. When an abstract from a meeting and a full article referred to the same trial, only the full article was included in the analysis. When there were multiple reports from the same trial, we used the most complete and/or recently reported data.
Inclusion and exclusion criteria
We included both observational studies and analyses from clinical trials. Randomized controlled trial was defined according to the National Library of Medicine criteria. Atrial fibrillation was defined either by electrocardiogram, self-report or international classification of diseases codes. Studies that did not report mortality were excluded. Data for each trial were abstracted by an investigator (W.T.Q.) and confirmed by a second investigator (M.A.). All discrepancies were identified and resolved by consensus, or as needed, with a third investigator (W.T.O.). Study quality. We followed the Preferred Reporting Items for Systematic reviews and MetaAnalyses (PRISMA) guidelines for systematic reviews and meta-analyses [6] . We did not use a proper scoring system to grade the study quality as strongly discouraged by the Cochrane Collaboration [7] .
Outcomes. The primary endpoint was allcause mortality. The secondary outcome was cardiovascular mortality. Data on endpoints were abstracted by Waquas Qureshi and Mouaz H. Al-Mallah. All disagreements were resolved by reaching consensus.
Statistical analysis. For all studies, we extracted the study baseline characteristics, event rates, hazard ratios (HR), and 95% confidence intervals (CI) for the primary and secondary outcomes. We extracted HRs for digoxin use in AF patients and all-cause mortality from published manuscripts and abstracts. The effect sizes were obtained from intention-to-treat analyses and fully adjusted models in the cohort studies.
The primary analysis measured the pooled estimate of mortality risk associated with digoxin use in AF patients. The secondary analysis measured the pooled estimate of risk for cardiovascular mortality. A stratified analysis for individuals with and without HF was also performed as HF patients with AF are more likely to be treated with digoxin due to its inotropic effect. Since we expected significant heterogeneity in the results, we also performed a pre-specified sensitivity analysis without observational studies.
To study heterogeneity, we hypothesized that the effect size may differ according to methodological quality of the studies. Thus, we used a random effects model by DerSimonian and Laird [8] . The random effects model assumes that the studies included in the meta-analysis are a random sample of hypothetical study populations. The random effects model provides a more conservative estimate of the combined data with a wider confidence interval and the summary statistic is less likely to be significant. The heterogeneity was assessed using the Cochrane Q statistic and the percentage of total variability due to true-between study heterogeneity was evaluated by using the I 2 measure. A p-value < 0.10 was considered significant for I 2 measure and interaction tests [9] . We performed meta-regression to examine if the natural log-transformed HR of the effect of digoxin use on mortality was influenced by the prevalence of HF. We used an unrestricted maximal likelihood method for mixed effects regression to evaluate for slope significance.
We assessed publication bias subjectively by visual inspection of Begg's funnel plot [10] and objectively by Egger's regression asymmetry test as funnel plots may be inaccurate in the assessment of very large studies [11, 12] . To address the possibility that "N" number of studies possibly were missing from our analysis and these studies, if included in the analysis, would shift the effect size towards the null, we used Orwin's fail-safe N formula. If the meta-analysis has captured all the relevant studies, then the funnel plot is expected to be symmetrical. However, if there is asymmetry in the plot, it is expected that there are some studies missing from the analysis. This asymmetry is addressed by Duval and Tweedie "trim and fill" method. For example, if there are more studies on the right-hand side and fewer studies on the left-hand side of the funnel plot, this would raise concern that these left-hand studies potentially exist. The Duval and Tweedie trim and fill method trims the right hand asymmetric studies to calculate an unbiased effect by an iterative procedure. It then fills the plot by re-introducing the right hand trimmed studies on the right as well as imputed counterparts to the left of the mean effect [13] . We reported the unbiased effect and the number of possible missing studies from the analysis. We also performed an additional cumulative analysis to evaluate if there was a temporal effect of the studies. Additionally, we evaluated removal of individual studies on the pooled HR. All analyses were performed using RevMan v. 5.0 and Comprehensive Meta-Analysis v. 2.2.4.
Results
We identified 1,543 studies during the initial literature search. After removing duplicates, 1,242 studies remained. After reading the abstracts and full text of the selected studies, 1,052 studies were discarded due to inability to meet inclusion criteria. Full review of 101 manuscripts and abstracts was performed and 24 studies were selected, 6 did not report the desired HRs and effect sizes to estimate our primary outcome. One of the studies was a patient-level meta-analysis of 4 trials [14] . Finally, 16 studies were selected with study data of 19 studies in this meta-analysis (Suppl. Fig. 1 ).
As mentioned above, there were 6 studies out of 16 that reported data from 9 clinical trials while other studies were observational in nature. There was 1 conference presentation and 1 conference abstract, while the remaining studies were either published or in online print. We used both of them separately. Study characteristics are presented in Table 1 . Studies mainly included males from white populations. Hypertension was the most frequent risk factor (39-100%) and only 1 study did not include patients with HF.
There were a total of 501,681 participants (mean age 73.8 years, males 62.3%), of whom 43,370 were enrolled in clinical trials and 458,311 included in observational studies. There were 414,116 patients with AF. There were 111,978 digoxin users and 389,643 participants who did not use digoxin. A breakdown for each study is presented in Supplementary Table 1 .
Using a random effects model, the risk of mortality was 27% higher in individuals using digoxin compared with persons who did not use digoxin (pooled HR: 1.27; 95% CI 1.19-1.36, p < 0.001) (Fig. 1) . When only subgroups of randomized clinical trials were analyzed, the risk for mortality for digoxin users increased to 46% (pooled HR: 1.46; 95% CI 1.09-1.94, p = 0.01) (Fig. 2 ). There was a high degree of heterogeneity in pooled studies (c 2 : 124, df = 14, p < 0.001; I 2 = 89%). When only studies with older individuals (n = 8; age > 70) who had a higher prevalence of HF (> 30%) were retained in the analysis, the heterogeneity became www.cardiologyjournal.org . Studies favoring use of digoxin are on the right hand side of the center line of no effect, while the studies against the use of digoxin are on the left hand side of the center line of no effect.
insignificant (c 2 : 7.10, df = 6, p = 0.31; I 2 = 16%). The AF Follow-Up Investigation of Rhythm Management (AFFIRM) trial had 2 published analyses. For primary analysis, we used the study with the larger subsample [15] , however in a sensitivity analysis with the smaller sub-study [16] , there was no significant difference in the pooled HRs (1.27; 95% CI 1.19-1.36 vs. 1.20; 95% CI 1.18-1.22, p for interaction = 0.11). Other subgroup analyses are shown in Supplementary Table 2. The risk of cardiovascular mortality associated with digoxin use was available in 9 studies. In a random effects model, digoxin use was associated with a 21% increased risk of mortality (pooled HR: 1.21; 95% CI 1.12-1.30, p < 0.001) with significant inter-study heterogeneity (I 2 = 74%, p < 0.001) (Suppl. Fig. 2 ). Removal of studies with < 30% of HF showed no heterogeneity (p > 0.1).
In a stratified analysis, the risk of mortality for individuals using digoxin in AF patients with HF was 21% higher (pooled HR: 1.21; 95% CI 1.07-1.36, p = 0.002; Fig. 3A ) compared with participants who did not use digoxin. The risk of mortality for individuals without HF was 47% higher for digoxin users (pooled HR: 1.47; 95% CI 1.25-1.73, p < 0.001; Fig. 3B ) than non-digoxin users.
Due to heterogeneity, a funnel plot was created to assess publication bias (Suppl. Fig. 3 ). The funnel plot showed minimal asymmetry that was quantified statistically by Egger's regression intercept (intercept: 1.16; 95% CI -0.76-3.08, df = 14, 1-tailed p-value: 0.11). Classical fail safe N was 1507, suggesting that there would need to be 1507 null studies with mean HR of 1.00 added to the analysis before the pooled effect would become non-significant. A more conservative method, Orwin's fail-safe N method was used to estimate the number of studies that would need to be added to the meta-analysis to make the pooled effect nonsignificant. For this reason, we assumed a mean HR of less than 0.90 for the potentially missing studies. Using this criterion, at least 29 studies would be needed to make the association between digoxin use and mortality non-significant. Using a trim and fill method, we needed to trim a study on the left of the mean which changed the pooled estimate from 1.28 (95% CI 1.20-1.37) to 1.26 (95% CI 1.18-1.35). There was no asymmetry on the right of the mean.
Additional analyses showed that there was a temporal effect present with more recent studies having lower effect sizes than older studies, however the direction and point estimate for the pooled HRs remained significant (Suppl. Fig. 4 ). When we removed one study from the analysis at each step of the analysis, the pooled estimate remained significant (Suppl. Fig. 5 ). In meta-regression analysis, proportion of HF in studies was inversely associated with risk of mortality associated with digoxin (slope: -0.008; 95% CI from -0.01 to -0.002, p = 0.02, Suppl. Fig. 6 ) suggesting HF modifies the risk of mortality and digoxin use.
Discussion
This comprehensive meta-analysis included 501,681 individuals and assessed the effect of digoxin use in AF patients in 9 randomized clinical trials and 10 observational cohorts. There were three main findings: 1) digoxin users with AF had a 27% increased risk of all-cause mortality, 2) digoxin users with AF had a 21% increased risk of cardiovascular mortality, and 3) digoxin users with AF who did not have HF had a relatively stronger association with risk of all-cause mortality (47% vs. 21%, p for interaction = 0.058) than digoxin users with HF.
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Several reports have examined the negative consequences of digoxin use resulting in a significant drop in digoxin use in acute myocardial infarction during the last two decades [17, 18] . Data supporting its use in chronic systolic HF have mainly come from two withdrawal studies [19, 20] , and the Digitalis Investigation Group trial that showed an absolute increase of 1.9% in cardiac death with digitalis (not including HF-related death) [21] . However, due to concomitant absolute reduction in HF-related mortality by 1.6%, the overall primary endpoint was not significant.
The aforementioned studies found an increased risk of all-cause mortality in conditions that are not limited to AF. Our results support these prior findings and extend prior work to show an increased risk of all-cause and cardiovascular mortalities exist for AF patients who use digoxin. Although the risks for the adverse outcomes examined were attenuated when we examined patients with HF, there was still a suggestion of 21% increased risk of all-cause mortality in these patients.
We also observed a downward temporal trend in reduced risk of mortality associated with digoxin use over the last 15 years. The reason for this difference is speculative but possibly related to the improved management of cardiovascular disease over the last decade [22] . Several of these studies have included individuals over periods of time, and have found a decreasing trend towards reduced prescription of digoxin by the clinicians [23] .
The exact mechanism underlying increased mortality risk observed with digoxin is unknown. Most of the reviewed studies did not evaluate the serum digoxin levels with mortality. Serum digoxin levels were significantly higher in those who died (1.151 vs. 0.935 ng/mL, p < 0.001) in one of the studies [24] . Renal function regulates serum digoxin levels and a subgroup analysis of AF--FIRM demonstrated increased mortality in digoxin Figure 3 . Forest plot of studies including atrial fibrillation patients with heart failure showing association of digoxin use with all-cause mortality. The computed weighted hazard ratios are depicted as boxes proportional to the size of the study. The bars depict the 95% confidence intervals (CI). Studies favoring use of digoxin are on the right hand side of the center line of no effect, while the studies against the use of digoxin are on the left hand side of the center line of no effect; A. Heterogeneity becomes insignificant after removing, LIFE, RIKS-HIA, RACE-II and Pastori study, I 2 = 40%, p = 0.14; B. Heterogeneity becomes insignificant after removing, LIFE, ATRIA-CVRN, RIKS-HIA and Pastori study, I 2 = 1%, p = 0.41.
users (HR: 1.28; 95% CI 1.25-1.31; p < 0.001).
Thus it can be speculated that higher serum levels of digoxin are related with the pathogenesis. Sudden cardiac death was also observed to be high in ROCKET-AF study and LIFE study in digoxin users. Sudden cardiac death is frequently due to fatal arrhythmia [25] . Digoxin was shown to increase arrhythmia-related deaths by 61% in post hoc analysis of AFFIRM trial [15] . Furthermore, we identified association of digoxin with cardiovascular mortality as well suggesting this observed mortality has cardiac basis rather than non-cardiovascular cause. This has been also previously demonstrated in a study without patients with AF [15] . Digoxin was shown to increase arrhythmia-related deaths by 61% in post hoc analysis of AFFIRM trial [15] . This study has several implications regarding management of AF in patients with and without HF. The burden of AF is increasing at dramatic pace with doubling AF by 2050. The annual mortality risk in AF is 3.84%, of which 37.4% occur due to cardiovascular conditions [26] . This analysis shows that at least 1/4 th of this risk is probably related to digoxin. A possible reduction in prescription of digoxin to these individuals may potentially improve overall survival of these patients. Even though the results have been consistent, this study still is limited by its exploratory design and thus calls for a randomized trial of digoxin in AF patients, with and without HF, to demonstrate its safety. However, it may be difficult to perform a randomized study at this point; a withdrawal study might be more suitable to confirm our findings. Additionally, this study suggests that there is a need to revisit the management guidelines of AF. There have been several changes in the management of HF and AF in the last decade. Management of AF in the light of recent evidence-based therapies may eventually lead to discarding the use of digoxin in these particular patients.
Limitations of the study
The current analysis should be interpreted in the context of several limitations. We did not have access to the source data for any of the studies used and the analysis was based on effect sizes and confidence intervals obtained from published studies. There was a significant heterogeneity in the population which remained unexplained and possibly is due to differences in the study samples examined. Also, the included studies from clinical trials were performed as post hoc analyses and potentially introduced bias into the current study. Bias by indication also is a significant limitation that should be considered while interpreting these results. Additionally, we were not able to assess the type of AF (e.g., paroxysmal, persistent, permanent) and the results may vary when accounting for this aspect of the arrhythmia. The exact doses of digoxin and other AF medications were unknown and possibly influenced the relationship between digoxin and the outcomes examined (e.g., drug--drug interactions) [27] .
Conclusions
The results from this pooled analysis suggest that digoxin use in AF is associated with an increased risk of all-cause and cardiovascular mortalities. Special consideration should be used by clinicians who use digoxin for rate control in patients with AF. Further study is needed to elucidate the underlying mechanism related to the increased risk of adverse events associated with digoxin. , and so on. Therefore, a decrement in the pooled estimate demonstrates a temporal decline in hazard ratio in published studies.
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Supplementary Figure 5.
One-study removal plot showing consistent estimates with removal of each study with each estimate. The corresponding hazard ratio in front of each study is the pooled hazard ratio after removal of that particular study. For example, the hazard ratio in front of LIFE 1997 is the pooled hazard ratio of all the other studies without including LIFE 1997. Such a plot demonstrates if one of the study has significant influential effect on the pooled estimates of meta-analysis. In a possible scenario, if a particular influential study is removed, the corresponding pooled hazard ratio may become insignificant. Here all of the corresponding pooled hazard ratios are significant, suggesting that none of the studies had particular influential effect on the pooled estimate.
Supplementary Figure 6 . Meta-regression plot showing a downsloping regression curve of hazard ratio across studies with increasing prevalence of heart failure patients for association of digoxin with mortality.
